DrugPatentWatch Database Preview
Patiromer sorbitex calcium - Generic Drug Details
What are the generic sources for patiromer sorbitex calcium and what is the scope of patent protection?
Patiromer sorbitex calcium
is the generic ingredient in one branded drug marketed by Relypsa Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Patiromer sorbitex calcium has one hundred and sixty-one patent family members in twenty-four countries.
One supplier is listed for this compound.
Summary for patiromer sorbitex calcium
| International Patents: | 161 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patiromer sorbitex calcium |
| DailyMed Link: | patiromer sorbitex calcium at DailyMed |
Pharmacology for patiromer sorbitex calcium
| Drug Class | Potassium Binder |
| Mechanism of Action | Potassium Ion Binding Activity |
Synonyms for patiromer sorbitex calcium
| 1415477-49-4 |
| Calcium, hydrolyzed divinylbenzene-Me 2-fluoro-2-propenoate-1,7-octadiene polymer sorbitol complexes |
| Cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol |
| Patiromer sorbitex calcium [USAN] |
| RLY5016S |
| Veltassa |
US Patents and Regulatory Information for patiromer sorbitex calcium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relypsa Inc | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-002 | Oct 21, 2015 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Relypsa Inc | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-001 | Oct 21, 2015 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Relypsa Inc | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-002 | Oct 21, 2015 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for patiromer sorbitex calcium
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2007531758 | Start Trial |
| European Patent Office | 1732524 | Start Trial |
| United Kingdom | 0906966 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for patiromer sorbitex calcium
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2957286 | LUC00094 | Luxembourg | Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 2365988 | PA2018004 | Lithuania | Start Trial | PRODUCT NAME: PATIROMERO, SORBITOLIO IR KALCIO KOMPLEKSAS IR JO DRUSKOS; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
| 2269589 | CA 2018 00003 | Denmark | Start Trial | PRODUCT NAME: PATIROMER AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179 20170721 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
Major Patent Expirations 2019 - 2020
NCE-1 Generic Application Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.